New data on navenibart, a potential HAE medicine currently being trialled, will be presented at the 2025 US HAEA Summit
The pharmaceutical company developing navenibart have announced that they have had four posters accepted for presentation at the 2025 US Hereditary Angioedema Association National Summit (HAEA).
The poster presentations will be:
- ALPHA-ORBIT – a Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Participants with Hereditary Angioedema (HAE).
- Long-Term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema (HAE): Initial Combined Results from ALPHA-STAR and ALPHA-SOLAR.
- Recruitment Challenges for Rare Disease Clinical Trials: A Systematic Review.
- Treatment with Navenibart (STAR-0215) Reduces Attack Severity and Use of Rescue Medication in Patients with Hereditary Angioedema (HAE): Interim Results from the ALPHA-STAR Trial.
(Source: Astria)